Health Advice



Insurers balk at paying for Biogen's $56,000-a-year Alzheimer's treatment

John Tozzi, Angelica LaVito and Anushree Dave, Bloomberg News on

Published in Health & Fitness

U.S. health insurers say they want more proof before paying for Biogen Inc.’s Aduhelm, stalling sales of the costly new Alzheimer’s therapy that the company hailed as a breakthrough for patients.

None of the 25 large insurers that responded to a Bloomberg News survey judged the $56,000-a-year drug “medically necessary,” a term used to describe treatments that are needed for specific ailments and meet medical standards. Most have deemed Aduhelm experimental, while some say they’re still evaluating it.

Insurers cited uncertainty about benefits and side effects for their denials. Still, Humana Inc., the nation’s second-largest Medicare insurer, is covering the drug for members who resemble those it helped in clinical trials.

Health insurers and government programs will play an outsize role as gatekeepers for Aduhelm, which the Food and Drug Administration approved despite objections from its scientific advisers and contradictory clinical trial results. Some patients are paying for the therapy out-of-pocket or seeking free supplies, while doctors who want to prescribe the drug must work hard to justify it.

For each person deemed eligible for Aduhelm, staffers can spend five hours trying to get insurers’ approval, said Paul Schulz, a doctor with the McGovern Medical School at UTHealth Houston and Memorial Hermann-Texas Medical Center. It’s rarely granted.

“It’s very difficult to spend that much time getting something approved on a case-by-case basis,” said Schulz, who’s treating about half a dozen people with Aduhelm. He’s received fees from Biogen for giving speeches.


Medicare, which covers 63 million elderly or disabled Americans, won’t set its final policy for Aduhelm until April, though the program is already raising premiums in anticipation of demand. Private insurers say they need more evidence that the treatment actually slows the rate at which Alzheimer’s patients deteriorate.

Aduhelm isn’t medically necessary for Alzheimer’s treatment “as a clinical benefit has not been established,” a representative for Health Care Service Corp. said in an email. The company has almost 17 million members in Blue Cross Blue Shield plans across five states, including Texas.

Biogen didn’t respond to requests for comment for this story.

Doctors, patients and families are desperate for relief from memory-robbing Alzheimer’s that affects some 6 million Americans, most of them elderly. Aduhelm removes amyloid plaques, protein deposits that are believed to play a role in the condition’s attack on the brain.


swipe to next page
©2021 Bloomberg L.P. Visit Distributed by Tribune Content Agency, LLC.